AI Article Synopsis

  • The Turkish Ministry of Health's smoking cessation program, started in 2011, provides varenicline and bupropion to eligible participants free of charge, with medication selection being random for consistent distribution.* -
  • A study with 405 participants assessed the effectiveness of these medications, measuring success in smoking cessation through CO levels and abstinence rates over a year, with follow-ups at various intervals.* -
  • Results showed higher cessation rates for participants on varenicline compared to those on bupropion, with 13.9% of varenicline users remaining smoke-free after one year, versus 6.2% for bupropion users, highlighting significant differences in medication efficacy.*

Article Abstract

Background: Within the context of the support program for smoking cessation, initiated by the Turkish Ministry of Health in 2011, those who present at 'smoking cessation' centres and are found to be suitable for pharmacological treatment are given varenicline and bupropion free of charge. As the smoking cessation programme is centralized, the selection of the medication is made randomly to provide a fixed distribution rate. The aim of this study was to evaluate the efficacy of both varenicline and bupropion in smoking cessation and to evaluate the effect of the smoking cessation programme.

Methods: A total of 405 individuals who met the study criteria were included in the study. Smoking habits and degree of dependence were determined in all the participants with the Fagerstrom test for nicotine dependence (FTND) and bupropion or varenicline therapy was initiated in those who were eligible. Patients were followed up at 15 days then at 1, 2, 3, 6 and 12 months after smoking cessation. A level of CO < 5 ppm and 'point prevalence abstinence' were used as the criteria of success for smoking cessation and this evaluation showed the non-smoking status in the previous 7 days.

Results: The mean age of the participants was 35.19 ± 7.73 years and 82.8% ( = 334) were male. Of the participants, 60.2% ( = 244) were given varenicline and 39.8% ( = 161) bupropion. The mean FTND and package/year was not significantly different between the groups. The rates of success in the 1st and 2nd weeks, and 1st, 3rd and 6th months were significantly higher in the varenicline group than in the bupropion group ( < 0.05). At the end of one year, the rate of smoking cessation was determined as 13.9% ( = 34) in the varenicline group and 6.2% ( = 10) in the bupropion gruop. The difference was statistically significant ( = 0.015). At the end of 1 year when the previous 7 days smoking status was evaluated with the 'point prevalence abstinence' measurement as the success criteria, success rates were 20.5% with varenicline and 18.6% with bupropion and the difference was not significant ( = 0.646). The individuals who used the medications for 45 days or longer were more successful in smoking cessation ( < 0.001). The most common reasons given for discontinuing the medication were the side-effects (31.5%). No significant difference was determined between the groups in respect of the side-effects observed.

Conclusions: Although the rates of smoking cessation in all the other control points were higher with varenicline than with bupropion, no significant difference was found between the success rates of varenicline and bupropion used in smoking cessation based on the last 7 days at the end of one year. Those who used the medications for 45 days or longer were more successful in smoking cessation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286845PMC
http://dx.doi.org/10.1186/s12971-017-0116-0DOI Listing

Publication Analysis

Top Keywords

smoking cessation
24
varenicline bupropion
12
efficacy varenicline
8
cessation programme
8
smoking
7
cessation
6
comparison efficacy
4
varenicline
4
bupropion
4
bupropion evaluation
4

Similar Publications

Objective: The purpose of this study was to evaluate repeated participation in hospital smoking cessation services and its related factors and to explore the correlation between the frequency of participation and its effectiveness in smoking cessation. This study uniquely follows participants over a seven-year period after the removal of financial barriers, with a maximum charge of TWD 200 (USD 6.4) for cessation medications in Taiwan.

View Article and Find Full Text PDF

Introduction: Due to decades of decentralisation of public health policies, local governments have been given increased tobacco control responsibilities across European countries. Previous studies suggest that implementing local tobacco control policies is not without challenges (e.g.

View Article and Find Full Text PDF

Background: The assessment of potential health effects of switching from cigarette smoking to non-combustible tobacco products has important implications for public health and regulatory decisions. Robust epidemiological evidence requires long-term follow-up of a large number of individuals. Real-world evidence derived from health records has the potential to help fill the gap in the interim.

View Article and Find Full Text PDF

Background: Canada has become the first country in the world to require warnings to be displayed on cigarette sticks. Tobacco companies were given a transition period, from 30 April to 31 July 2024 to ensure that all king size cigarettes sold in the country included warnings on the filter of each cigarette stick. Warnings on the filter of regular size cigarettes will be implemented from April 2025.

View Article and Find Full Text PDF

Introduction: In 2003, the World Health Organization (WHO) recommended that pictorial warnings on tobacco products be used to educate consumers on the negative health impacts associated with tobacco use. This study aimed to assess the effectiveness of pictorial warnings on cigarette packaging among smokers and non-smokers.

Methods: A cross-sectional study using a self-administered questionnaire was conducted in Kuala Lumpur.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: